Reevaluation of assay methods and establishment of kit for superoxide dismutase activity
In vascular injury models, BPC-157 promotes healing of blood vessel damage and prevents pathological thrombus formation while supporting physiological hemostasis
For orthopedic patients, this could mean faster recovery from tendon or ligament injuries, improved outcomes after orthopedic procedures, and reduced downtime for athletes and active individuals
Scientific Sources Frequently Asked Questions Expand the questions below Once submitted, a state-licensed MD or DO will review your intake and determine the most appropriate treatment plan for you
BPC-157 has been studied primarily in preclinical and experimental settings, where it has demonstrated potential benefits in accelerating wound healing, improving gut integrity, and supporting joint and soft tissue health
However, some secondary measures of nerve impairment did improve, especially in participants with higher cardiovascular risk and moderate BMI.7 Shorter-term trials have shown that 600mg/day of oral racemic ALA reduced neuropathy symptoms like burning, tingling, and numbness in as little as 35 weeks.4 20 A 2010 meta-analysis concluded that oral ALA can improve symptoms of diabetic neuropathy, but noted variability in effect sizes across trials and better results with intravenous administration.1 Despite promising results from some trials, a recent systematic review evaluating eight randomized controlled trials indicates that findings on ALA's effectiveness in treating diabetic neuropathy symptoms are inconsistent.23 While ALA proved safe and tolerable across these studies, the review concluded that definitive evidence supporting significant benefits is limited
